Adherence to the Minimum Data Set Suggested by American Urological Association Guidelines for the Surgical Treatment of Stress Urinary Incontinence.

OBJECTIVE: To assess contemporary adherence to the minimum data set proposed for future publication in the 1997 American Urological Association (AUA) guidelines on the surgical management of female SUI in 1997. guidelines among recently published literature. MATERIALS AND METHODS: We reviewed all publications included in the AUA/SUFU Surgical Treatment of Female SUI Guidelines and included articles that reported surgical outcomes for SUI treatment. They were abstracted for the reporting of the previously defined 22 data points. Each article received a compliance score as a percent of parameters met out of the 22 data points. RESULTS: Three hundred eighty articles from the 2017 AUA guidelines search, in combination with an independent updated literature search were included. There was an average compliance score of 62%. The best compliance rates for individual data points were: defined criteria for success (95%) and patient history (97%). The lowest compliance rates were: minimum follow-up >48 months (8%) and post-treatment micturition diary (17%). There was no difference between mean rates of reporting for articles before and after the SUFU/AUA 2017 guidelines (61% pre vs 65% post). CONCLUSION: Adherence to reporting the most recent minimum standards in the current SUI literature is largely suboptimal. This apparent lack of compliance may suggest a role for a more stringent editorial review process, or alternatively that the prior suggested data set was overly burdensome and/or irrelevant.

A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.

OBJECTIVE: There is increasing evidence that cognitive impairment is common in patients with bipolar disorder. The purpose of this study was to determine whether galantamine augmentation improved cognition in patients with euthymic bipolar disorder. In addition, the effect of galantamine on clinical measures of functioning and psychopathology was assessed. METHOD: This study was a randomized double-blind, placebo-controlled, parallel design examining the impact of galantamine augmentation on cognition and other clinical measures in 30 patients during the course of 3 months. Sixteen subjects who completed baseline and follow-up second neuropsychological testing were evaluable (10 with galantamine and 6 with placebo). RESULTS: The galantamine group showed improved performance on the California Verbal Learning Test total learning and the placebo group showed improved performance on the 2 Delis-Kaplan Executive Functioning System trail-making conditions and category fluency. CONCLUSIONS: Episodic memory performance was improved in the galantamine treatment group but did not improve in the placebo group. In contrast, performance on 2 of the processing speed measures showed significant improvement in the placebo condition, whereas that of the patients treated with galantamine did not improve. Galantamine may thus have specific benefits for episodic memory, but not processing speed, in patients with cognitive impairment as part of bipolar disorder.

Subjective well-being in urban adolescents of color.

Relationships among predictors and criteria of subjective well-being were examined in a sample of 151 urban adolescents of color, ages 12-15. The relative strengths of family, peer, and school-related support and esteem in predicting three measures of subjective well-being (life satisfaction, positive affect, and negative affect) were explored. Results suggested that sense of worth in one's family explained a significant amount of variance in subjective well-being variables, above and beyond the contributions of individual, school, and peer-related variables. Implications for prevention and mental health promotion with urban adolescents of color are discussed based on these findings.

Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study.

OBJECTIVE: To determine the efficacy of divalproex (extended release) in the treatment of acute nonrefractory bipolar depression. METHOD: In a stratified, double-blind, randomized, placebo-controlled trial, 18 acutely depressed bipolar outpatients (DSM-IV criteria) received either divalproex monotherapy (target dose level, 70-90 ng/dL) (N = 9) or placebo (N = 9) for 6 weeks. Patients were recruited between January 2004 and May 2005. Clinical assessment on the Montgomery-Asberg Depression Rating Scale (MADRS) determined primary efficacy. RESULTS: The divalproex treatment group showed significantly greater reduction in MADRS scores compared to placebo (group x time interaction, p = .0078). Absolute effect size of estimated MADRS total score reduction over time was 13.6 points with divalproex versus 1.4 points with placebo (p = .003, linear growth curve model). Standardized effect size was large (Cohen d = 0.81). MADRS item analyses demonstrated improvement in core mood symptoms more than in anxiety or insomnia symptoms. There was also a modest but significant association between MADRS and Mania Rating Scale scores in the divalproex group (r = 0.29, df = 51, p = .03), but not in the placebo group (r = -0.15, df = 35, p = .36). CONCLUSIONS: Divalproex appeared to be an effective treatment for acute nonrefractory bipolar depression, which is consistent with previous small randomized studies. Some evidence of benefit in the depressive mixed state was observed. Confirmation or refutation with larger randomized clinical trials is warranted. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00226343.